NCT02228733View on ClinicalTrials.gov

Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074

PHASE1CompletedINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions

Healthy

Interventions

DRUG

KBP-5074

Comparisons of different doses of study drug

Sponsors

Lead Sponsor

KBP Biosciences

All Listed Sponsors

lead

KBP Biosciences

INDUSTRY

NCT02228733 - Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074 | Biotech Hunter | Biotech Hunter